TITLE

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

AUTHOR(S)
Cheng, S; Ma, J; Guo, A; Lu, P; Leonard, J P; Coleman, M; Liu, M; Buggy, J J; Furman, R R; Wang, Y L
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p649
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular mechanisms of action would shed light on CLL pathophysiology and provide additional opportunities for the development of new therapies. In this study, we have chosen an in vivo approach by employing an ongoing phase 1b trial of ibrutinib. We prospectively collected and analyzed serial samples from the CLL patients before and after the initiation of ibrutinib. We found that the blockage of cell proliferation was one of the primary effects of ibrutinib against leukemic CLL cells in vivo. Using a co-culture system that induces CLL proliferation in vitro, analysis of several parameters, including Ki-67 expression and bromodeoxyuridine (BrdU) incorporation, revealed that the proliferation of CLL cells was directly inhibited by ibrutinib. Furthermore, activities of BTK and phospholipase Cγ2 as well as downstream signaling molecules, AKT and ERK, were all coordinately downregulated over time in ibrutinib-treated patients. Our findings suggest that the cell proliferation is one of the essential properties of CLL. Blocking cell proliferation via inhibition of BTK-mediated signaling may contribute to clinical responses in ibrutinib-treated patients.
ACCESSION #
94762962

 

Related Articles

  • Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Rendeiro, André F.; Krausgruber, Thomas; Fortelny, Nikolaus; Zhao, Fangwen; Penz, Thomas; Farlik, Matthias; Schuster, Linda C.; Nemc, Amelie; Tasnády, Szabolcs; Réti, Marienn; Mátrai, Zoltán; Alpár, Donát; Bödör, Csaba; Schmidl, Christian; Bock, Christoph // Nature Communications;1/29/2020, Vol. 11 Issue 1, p1 

    The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To define the underlining regulatory dynamics, we analyze high-resolution time courses of ibrutinib treatment...

  • Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas. Alinari, L; Quinion, C; Blum, KA // Clinical Pharmacology & Therapeutics;May2015, Vol. 97 Issue 5, p469 

    The B-cell receptor pathway (BCR) is aberrantly activated in select B-cell malignancies. This knowledge has allowed for the development of inhibitors of different crucial steps of this pathway. Bruton's tyrosine kinase (BTK) is a key component of BCR signaling and functions as an important...

  • Targeting Bruton's tyrosine kinase in B cell malignancies. Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P. // Nature Reviews Cancer;Apr2014, Vol. 14 Issue 4, p219 

    Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in...

  • Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Herman, S E M; Barr, P M; McAuley, E M; Liu, D; Wiestner, A; Friedberg, J W // Leukemia (08876924);Aug2013, Vol. 27 Issue 8, p1769 

    The article presents a study which examines whether fostamatinib inhibits B-cell receptor (BCR) signaling, activates cells in vivo, and disrupts cell proliferation in patients with chronic lymphocytic leukemia (CLL). Findings reveal the capacity of fostamatinib to inhibit BCR signal transduction...

  • Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Wang, Y; Zhang, LL; Champlin, RE; Wang, ML // Clinical Pharmacology & Therapeutics;May2015, Vol. 97 Issue 5, p455 

    The B-cell receptor signaling pathway, which is critical to the development and maturation of normal B-cells, is emerging as an attractive therapeutic target in B-cell malignancies. Ibrutinib is a potent irreversible inhibitor of Bruton's tyrosine kinase (Btk), a key kinase important for signal...

  • BRAF inhibitor--associated ERK activation drives development of chronic lymphocytic leukemia. Yaktapour, Niuscha; Meiss, Frank; Mastroianni, Justin; Zenz, Thorsten; Andrlova, Hana; Mathew, Nimitha R.; Claus, Rainer; Hutter, Barbara; Fröhling, Stefan; Brors, Benedikt; Pfeifer, Dietmar; Pantic, Milena; Bartsch, Ingrid; Spehl, Timo S.; Meyer, Philipp T.; Duyster, Justus; Zirlik, Katja; Brummer, Tilman; Zeiser, Robert // Journal of Clinical Investigation;Nov2014, Vol. 124 Issue 11, p5074 

    Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to...

  • X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. Hoshino, Akihiro; Okuno, Yusuke; Migita, Masahiro; Ban, Hideki; Yang, Xi; Kiyokawa, Nobutaka; Adachi, Yuichi; Kojima, Seiji; Ohara, Osamu; Kanegane, Hirokazu // Journal of Clinical Immunology;Feb2015, Vol. 35 Issue 2, p108 

    X-linked agammaglobulinemia (XLA) is clinically characterized by reduced number of peripheral B cells and diminished levels of serum immunoglobulins, and caused by a mutation in the Bruton' s tyrosine kinase ( BTK) gene, which play a pivotal role in signal transduction of pre-B-cell receptor...

  • BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. Haerzschel, Andrea; Catusse, Julie; Hutterer, Evelyn; Paunovic, Manuela; Zirlik, Katja; Eibel, Hermann; Krenn, Peter; Hartmann, Tanja; Burger, Meike; Krenn, Peter W; Hartmann, Tanja N // Annals of Hematology;Dec2016, Vol. 95 Issue 12, p1979 

    Dysregulation of B cell receptor (BCR) signalling is a hallmark of chronic lymphocytic leukaemia (CLL) pathology, and targeting BCR pathway kinases has brought great therapeutic advances. Activation of the BCR in lymphoid organs has been associated with CLL cell proliferation and survival,...

  • ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Scielzo, C.; Camporeale, A.; Geuna, M.; Alessio, M.; Poggi, A.; Zocchi, M. R.; Chilosi, M.; Caligaris-Cappio, F.; Ghia, P. // Leukemia (08876924);Apr2006, Vol. 20 Issue 4, p689 

    ZAP-70 tyrosine kinase is involved in signalling pathways following T-cell receptor stimulation and was originally described only in T cells and natural killer cells. ZAP-70 expression has been reported in normal mouse B lineage cells and in human malignant B lymphocytes, mainly in chronic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics